U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23N5O
Molecular Weight 397.4723
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVOCERANIB

SMILES

O=C(NC1=CC=C(C=C1)C2(CCCC2)C#N)C3=CC=CN=C3NCC4=CC=NC=C4

InChI

InChIKey=WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)

HIDE SMILES / InChI

Approval Year

Unknown
86413
Name Type Language
RIVOCERANIB
INN  
Official Name English
rivoceranib [INN]
Common Name English
RIVOCERANIB [USAN]
Common Name English
3-PYRIDINECARBOXAMIDE, N-(4-(1-CYANOCYCLOPENTYL)PHENYL)-2-((4-PYRIDINYLMETHYL)AMINO)-
Systematic Name English
YN968D1 FREE BASE
Code English
APATINIB
Common Name English
N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
Systematic Name English
APATINIB FREE BASE
Common Name English
Rivoceranib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
FDA ORPHAN DRUG 798720
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
FDA ORPHAN DRUG 682618
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
NCI_THESAURUS C1742
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
Code System Code Type Description
DRUG CENTRAL
5211
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
DRUG BANK
DB14765
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
USAN
FG-23
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
INN
10596
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
CAS
811803-05-1
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
EVMPD
SUB183841
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
PUBCHEM
11315474
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
FDA UNII
5S371K6132
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
SMS_ID
100000170007
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
EPA CompTox
DTXSID601024366
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
NCI_THESAURUS
C152237
Created by admin on Sat Dec 16 02:11:04 UTC 2023 , Edited by admin on Sat Dec 16 02:11:04 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of RIVOCERANIB
METABOLITE (PARENT)
Structure of 3-HYDROXY-APATINIB, CIS-
METABOLITE (PARENT)
Structure of APATINIB-25-N-OXIDE
SALT/SOLVATE (PARENT)
Structure of Rivoceranib Mesylate
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966